About this trial
This single-center pilot study will evaluate the accuracy and feasibility of non-invasive cardiac output measurement using the UltraTrac device in pediatric patients aged 0-21 years undergoing standard-of-care diagnostic cardiac catheterization. UltraTrac integrates ultrasound with impedance cardiography (ICG) to refine stroke volume and cardiac output calculations. During catheterization, trained staff will apply four surface-skin electrodes and a Doppler probe and obtain UltraTrac measurements without altering standard clinical care. The primary objective is to assess concordance between algorithm-derived cardiac output and gold-standard invasive measurements (Fick or thermodilution). The secondary objective is to evaluate human-factors issues reported by clinicians during device use. The study will enroll 50 hemodynamically stable pediatric participants, with up to 60 screened to account for screen failures. UltraTrac poses no more than minimal risk, using noninvasive sensors comparable to standard electrocardiogram (ECG) and Doppler procedures. Measurements will be performed only when clinically appropriate, and no UltraTrac data will be used to guide patient care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Provision of signed and dated parental permission form (for patients <18) or informed consent form (for patients >= 18 years)
Provision of verbal (for patients 7-11) or signed and dated assent form (for patients 12-17)
Stated willingness to comply with all study procedures
Male or female, aged 0 - 21 years
Disqualifiers
Weight less than 2.5kg
Patients who are hemodynamically unstable, as assessed by the attending physician
Broken skin or poor skin integrity that would prohibit safe adhesion of electrodes or Doppler probe
Known moderate-to-severe reactions to electrocardiogram electrode adhesives or ultrasound gel
Trial population
Pediatric patients aged 0-21 years who are hemodynamically stable and undergoing cardiac catheterization as part of standard of care at Children's National Hospital in Washington, DC.
Trial design
Cohort
Prospective
Treatments tested in this trial
Noninvasive Hemodynamic Monitoring System
DeviceThis study involves the use of a noninvasive hemodynamic monitoring system that integrates impedance cardiography with Doppler ultrasound to measure cardiac function. The system uses standard adhesive electrodes placed on the skin and a small ultrasound sensor positioned over the carotid artery. During each measurement period, the system collects impedance waveforms and ultrasound timing signals to estimate stroke volume, cardiac output, and left ventricular ejection time. The UltraTrac is used only for physiologic monitoring and data collection. Study data are not used to deliver therapy, influence clinical care, or provide diagnostic information to participants or clinicians.
Treatment groups
Trial outcomes
Primary outcomes
Concordance between algorithm-derived measurements and standard measurements.
Secondary outcomes
Study staff and physician procedural issues captured via structured reporting form
Qualitative and quantitative documentation of issues encountered during the procedure, including number and type of issue, collected through a structured reporting form completed by study staff and physicians.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
AcQumen Medical, Inc.
Lead sponsor
Children's National Research Institute
Collaborator
This trial is not recruiting at the moment. You can still explore other options: